UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016852
Receipt number R000019542
Scientific Title Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
Date of disclosure of the study information 2015/03/23
Last modified on 2020/07/01 18:16:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer

Acronym

Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer

Scientific Title

Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer

Scientific Title:Acronym

Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer

Region

Japan


Condition

Condition

locally advanced unresectable pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of first line GEM+ nab-PTX combination therapy for locally advanced pancreatic cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Response rate

Key secondary outcomes

Overall survival, progression free survival, adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Patients receiving nab-PTX plus gemcitabine will receive 125 mg/m2, nab-PTX as a 30- to
40-minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30- to 40-minute infusion (maximum 40 minutes) for 3 weeks followed by a week of rest.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1) Histlogically proven adenocarcinoma or adeno-squamous carcinoma
2) Unresectable locally advanced pancreatic cancer
3) No prior chemotherapy and radiotherapy for other malignancies
4) Age upper 20 and less than 80
5) ECOG performance status of 0, 1
6) Adequate hematologic, hepatic and renal function
7) Written informed consent

Key exclusion criteria

1) Patients with Distant metastasis
2) Patients with symptomatic pulmonary fibrosis or interstitial pneumonia
3) Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
4) Patients has severe complications, such as heart failure, renal failure ileus and severe mental disorder
5) History of malignancy in the last 3 years
6) History of Peripheral Artery Disease (eg, claudication, Leo Buerger's disease).
7) History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa).
8) Women who are pregnant or expect to be pregnant, or nursing female
9) Others

Target sample size

24


Research contact person

Name of lead principal investigator

1st name Takuji
Middle name
Last name Torimura

Organization

Kurume university school of medicine

Division name

Division of gastroenterology

Zip code

8300011

Address

Kurume-shi

TEL

0942-31-7561

Email

takahashi_kenjirou@med.kurume-u.ac.jp


Public contact

Name of contact person

1st name Masaru
Middle name
Last name Fukahori

Organization

Kurume university school of medicine

Division name

Division of gastroenterology, multidisciplinary cancer treatment center

Zip code

830-0011

Address

67 Asahi-machi, Kurume city, Fukuoka

TEL

0942-31-7561

Homepage URL


Email

digdug0526@gmail.com


Sponsor or person

Institute

Kurume university school of medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethical Committee of Kurume University

Address

67 Asahi-machi, Kurume city, Fukuoka

Tel

0942-31-7917

Email

aro_crc@kurume-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

久留米大学病院(福岡県)


Other administrative information

Date of disclosure of the study information

2015 Year 03 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 03 Month 20 Day

Date of IRB

2015 Year 03 Month 16 Day

Anticipated trial start date

2015 Year 03 Month 23 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry

2020 Year 03 Month 31 Day

Date trial data considered complete

2020 Year 03 Month 31 Day

Date analysis concluded

2020 Year 04 Month 03 Day


Other

Other related information



Management information

Registered date

2015 Year 03 Month 20 Day

Last modified on

2020 Year 07 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019542


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name